We recognize that critical care clinicians fight every day to save patients from the cytokine storm. This deadly threat has taken too many organs and too many lives. The severity of this threat is our call to action. We leverage our scientific expertise and resources to break past limitations of current therapies and help our heroes in critical care stop the cytokine storm and save precious lives.
Bring organ-saving, lifesaving solutions to critically ill patients under attack by a cytokine storm
Elevate the standard of care in acute and chronic hyperinflammatory conditions with innovations that transform patient outcomes on a global scale
Professor, Division of Nephrology, Internal Medicine
Center for Integrative Research in Critical Care
University of Michigan
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Our first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic-like condition in critically ill pediatric patients. Our Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. We are currently conducting a pivotal trial of our SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
©SeaStar Medical 2025
